Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva is well-positioned in the competitive biopharmaceutical industry with a strong research and development team focused on developing innovative treatments for MASH, a growing health concern globally. With a diversified pipeline and a solid financial standing, particularly in comparison to other smaller biotech companies, Inventiva has the potential to bring highly valuable therapies to patients and generate significant returns for investors. Additionally, the promising results of their lead drug candidate, lanifibranor, in phase 2 trials for MASH treatment show strong potential for market success and further expansion into other related disease areas.

Bears say

Inventiva is currently operating in a highly competitive market with several other companies also developing drugs for MASH. The company's lanifibranor has shown some promising data in Phase 2 and 3 trials, but it will face challenges in differentiating itself from competitors and gaining market share. Additionally, the need for ongoing capital raises to fund clinical trials and commercialization poses a significant risk for the company's financial stability.

Inventiva S.A. (IVA) has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Strong Buy based on their latest research and market trends.

According to 8 analysts, Inventiva S.A. (IVA) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.